Literature DB >> 2551194

Human selenite metabolism: a kinetic model.

B H Patterson1, O A Levander, K Helzlsouer, P A McAdam, S A Lewis, P R Taylor, C Veillon, L A Zech.   

Abstract

A model is developed to describe the kinetics of sodium selenite metabolism in humans, based on plasma, urine, and fecal samples obtained from six subjects over a 4-wk period after a single oral 200-micrograms dose of the enriched stable isotope tracer 74Se. The model describes absorption, distributed along the gastrointestinal tract, and enterohepatic recirculation. The model includes four kinetically distinct plasma components, a subsystem consisting of the liver and pancreas, and a slowly turning-over tissue pool. For the six subjects, the ranges of mean residence times for the four plasma components are, respectively, 0.2-1.1 h, 3-8 h, 9-42 h, and 200-285 h; for the hepatopancreatic subsystem 4-41 days; and for the tissue pool 115-285 days. Approximately 84% of the administered dose was absorbed, and after 12 days approximately 65% remained in the body. The model predicts that after 90 days approximately 35% of this Se would be retained, primarily in the tissues. Separating Se metabolism into several distinct kinetic components is a first step in identifying the efficacious, nutritious, and toxic forms of the element.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2551194     DOI: 10.1152/ajpregu.1989.257.3.R556

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  12 in total

1.  A human model of selenium that integrates metabolism from selenite and selenomethionine.

Authors:  Meryl E Wastney; Gerald F Combs; Wesley K Canfield; Philip R Taylor; Kristine Y Patterson; A David Hill; James E Moler; Blossom H Patterson
Journal:  J Nutr       Date:  2011-02-02       Impact factor: 4.798

Review 2.  Selenium metabolism and bioavailability.

Authors:  L A Daniels
Journal:  Biol Trace Elem Res       Date:  1996-09       Impact factor: 3.738

Review 3.  Selenium in thyroid disorders - essential knowledge for clinicians.

Authors:  Kristian Hillert Winther; Margaret Philomena Rayman; Steen Joop Bonnema; Laszlo Hegedüs
Journal:  Nat Rev Endocrinol       Date:  2020-01-30       Impact factor: 43.330

4.  Methyl selenocysteine: single-dose pharmacokinetics in men.

Authors:  James R Marshall; Clement Ip; Karen Romano; Gerald Fetterly; Marwan Fakih; Borko Jovanovic; Marjorie Perloff; James Crowell; Warren Davis; Renee French-Christy; Alexander Dew; Margerie Coomes; Raymond Bergan
Journal:  Cancer Prev Res (Phila)       Date:  2011-08-16

5.  The inhibitory effect of sodium selenite on N-nitrosodiethylamine-induced and phenobarbital promoted liver tumourigenesis in rats based on the modulation of polyamine levels.

Authors:  C Thirunavukkarasu; K Premkumar; R Jagadeeswaran; D Sakthisekaran
Journal:  Mol Cell Biochem       Date:  2005-12       Impact factor: 3.396

Review 6.  Selenium: an element for life.

Authors:  Leonidas H Duntas; Salvatore Benvenga
Journal:  Endocrine       Date:  2014-12-18       Impact factor: 3.633

7.  Selenium toxicity from a misformulated dietary supplement, adverse health effects, and the temporal response in the nail biologic monitor.

Authors:  John Steven Morris; Stacy B Crane
Journal:  Nutrients       Date:  2013-03-28       Impact factor: 5.717

8.  Maternal diet and selenium concentration in human milk from an Italian population.

Authors:  Francesca Valent; Milena Horvat; Darja Mazej; Vekoslava Stibilj; Fabio Barbone
Journal:  J Epidemiol       Date:  2011-05-28       Impact factor: 3.211

9.  Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men.

Authors:  James R Marshall; Raymond F Burk; Rochelle Payne Ondracek; Kristina E Hill; Marjorie Perloff; Warren Davis; Roberto Pili; Saby George; Raymond Bergan
Journal:  Oncotarget       Date:  2017-04-18

10.  Selenium Kinetics in Humans Change Following 2 Years of Supplementation With Selenomethionine.

Authors:  Blossom H Patterson; Gerald F Combs; Philip R Taylor; Kristine Y Patterson; James E Moler; Meryl E Wastney
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-29       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.